A Study for Identification of Immune Determinants for Response to Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
Latest Information Update: 04 Jan 2024
At a glance
- Drugs Nivolumab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Biomarker; Therapeutic Use
- 27 Jan 2022 Planned End Date changed from 1 Dec 2022 to 1 Feb 2023.
- 27 Jan 2022 Planned primary completion date changed from 1 Jun 2022 to 1 Dec 2022.
- 27 Jan 2022 Status changed from not yet recruiting to active, no longer recruiting.